IP Library › Granted Patent US 11,883,393
Granted Patent B2
US 11,883,393 · App. 17/126,501 · Granted Jan 30, 2024

Compounds and methods for the targeted degradation of androgen receptor

Inventors: Lawrence B. Snyder (Killingworth, CT); Hanqing Dong (Madison, CT)
Assignee: Arvinas Operations, Inc.
A61K31/496A61K31/167A61K31/277A61K31/337A61K31/417A61K31/4523A61K31/4545A61K31/497A61K31/501A61K31/506A61K31/5377A61K31/5386A61K31/57A61K31/661A61K31/663A61K31/675A61K38/09A61K47/545C07D401/12C07D401/14C07D413/12C07D413/14C07D498/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,883,393
App. No.
17/126,501
Granted
Jan 30, 2024
Kind
B2
Abstract

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

Claims (4)

1. A compound that is:

2. A pharmaceutically acceptable salt of a compound that is:

3. A pharmaceutical composition comprising a compound and one or more pharmaceutically acceptable excipients, wherein the compound is:

4. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound and one or more pharmaceutically acceptable excipients, wherein the compound is:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: SNYDER, LAWRENCE B.; CREW, ANDREW P.; WANG, JING; DONG, HANQING
To: ARVINAS OPERATIONS, INC.
Reel/Frame 055140/0837 →
Continuity (4)
Provisional Application 63089497 · Oct 8, 2020
Provisional Application 63032473 · May 29, 2020
Provisional Application 62950815 · Dec 19, 2019
Related Publication 20210196710A1 · Jul 1, 2021
Cited By (3)
US 12,310,975 US 12,427,144 US 12,441,708